lung cancer

Polypharmacy is highly prevalent among adults with cancer and multimorbidity, and is associated with high health ...

MARCH 22, 2025

The bispecific antibody Rybrevant plus Lazcluze significantly extended overall survival in patients with locally ...

MARCH 17, 2025

The bispecific antibody amivantamab-vmjw (Rybrevant, Janssen/Johnson & Johnson) plus lazertinib (Lazcluze, ...

JANUARY 10, 2025

Only slightly more than one-third of people diagnosed with non-small cell lung cancer receive personalized ...

DECEMBER 16, 2024

The next two years may well see an explosion of FDA approvals for non-small cell lung cancer, with some of the ...

DECEMBER 15, 2024

Only slightly more than one-third of patients diagnosed with non-small cell lung cancer receive personalized ...

OCTOBER 16, 2024

Rigel Pharmaceuticals announced that it has entered into a definitive agreement to acquire the U.S. rights to ...

MAY 20, 2024

In the United States, lung cancer is the second most commonly diagnosed cancer, with more than 236,000 patients ...

NOVEMBER 14, 2022

The FDA granted Tabrecta regular approval for adults with metastatic NSCLC with mutations leading to ...

AUGUST 17, 2022

The FDA granted a new indication for trastuzumab deruxtecan-nxki (Enhertu, AstraZeneca/Daiichi Sankyo) to treat ...

AUGUST 15, 2022

The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) in combination with platinum-doublet chemotherapy to ...

APRIL 12, 2022

The FDA approved the use of ramucirumab (Cyramza, Lilly) in combination with erlotinib for first-line treatment of ...

JUNE 3, 2020